Fumarate analogs and uses thereof

US9475781B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9475781-B2
Application numberUS-201514815589-A
CountryUS
Kind codeB2
Filing dateJul 31, 2015
Priority dateAug 4, 2014
Publication dateOct 25, 2016
Grant dateOct 25, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (A): wherein either: Y 1 is X a and Y 2 is hydrogen, or Y 2 is X a and Y 1 is hydrogen; wherein X a is selected from carboxylic acid, carboxyl ester, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl; and R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (A); or a salt or stereoisomer thereof. 2. The compound of claim 1 , wherein the compound is of formula (Ia) or (Ib): wherein R 15 comprises a linking group and a compound of formula (Ia) or (Ib). 3. The compound of claim 1 , wherein X a is a substituted heterocyclyl or a substituted heteroaryl, wherein the substituent on X a is X 1 , wherein X 1 is C 1-6 alkyl or a progroup. 4. The compound of claim 1 , wherein the compound is a compound of formula (IIa) or (IIb): wherein R 1 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and —R 15 , wherein R 15 comprises a linking group and a compound of formula (IIa) or (IIb); and X 1 is hydrogen, C 1-6 alkyl or a progroup; or a salt or stereoisomer thereof. 5. The compound of claim 4 , wherein R 1 is aryl, substituted aryl, heteroaryl, or substituted heteroaryl. 6. The compound of claim 4 , wherein R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl. 7. The compound of claim 6 , wherein R 1 is hydrogen, methyl, ethyl, isopropyl, cyclopentyl, 4-tetrahydropyranyl, —CH 2 CH 2 OCH 3 , —CH 2 OCH 3 , —CH 2 C(O)OCH 3 , or —CH 2 CH(CH 3 ) 2 OH. 8. The compound of claim 3 , wherein X 1 is C 1-6 alkyl. 9. The compound of claim 7 , wherein X 1 is methyl or tert-butyl. 10. The compound of claim 3 , wherein X 1 is a progroup of the formula: wherein L 1 is a linking group; X 2 is optional and selected from O, N and S; R 2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, acyl, aminoacyl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and R 3 and R 4 are each independently optional and selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, oxo, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or R 2 together with X 2 and either R 3 or R 4 form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl. 11. The compound of claim 10 , wherein X 1 is selected from: wherein L 1 is a C 1-6 alkyl or substituted C 1-6 alkyl; R 5 and R 6 are each independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; or R 5 and R 6 together with the nitrogen to which they are attached form a heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl; and R 7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and —OR 14 where R 14 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl. 12. The compound of claim 11 , wherein X 1 is selected from: wherein R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen, alkyl and substituted alkyl. 13. The compound of claim 12 , wherein R 8 and R 9 are each independently selected from hydrogen and C 1-6 alkyl. 14. The compound of claim 13 , wherein R 8 and R 9 are each hydrogen. 15. The compound of claim 13 , wherein R 8 is hydrogen and R 9 is C 1-6 alkyl. 16. The compound of claim 12 , wherein R 10 , R 11 , R 12 and R 13 are each independently selected from hydrogen and C 1-6 alkyl. 17. The compound of claim 16 , wherein R 10 , R 11 , R 12 and R 13 are each hydrogen. 18. The compound of claim 16 , wherein one of R 10 , R 11 , R 12 and R 13 is methyl and the remaining are hydrogen. 19. The compound of claim 16 , wherein two of R 10 , R 11 , R 12 and R 13 are methyl and the remaining are hydrogen. 20. The compound of claim 1 , wherein the linking group is —(CH 2 ) n —Z y —(CH 2 ) m —, wherein n is an integer from 1 to 6; m is 0 or an integer from 1 to 6; y is 0 or 1; and Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—. 21. The compound of claim 20 , wherein the compound has one of the following formulae: wherein X 1a and X 1b are each independently selected from C 1-6 alkyl and a progroup; and Z is O, NH, —O—P(O)(OH)—O—, S, S(O), SO 2 or —O—S(O) 2 —O—. 22. The compound of claim 1 , wherein R 1 is: wherein X 1b is selected from C 1-6 alkyl and a progroup. 23. The compound of claim 22 , wherein the compound has one of the following formulae: wherein X 1 and X 1b are each independently selected from C 1-6 alkyl and a progroup. 24. The compound of claim 23 , wherein X 1 and X 1b are each independently a C 1-6 alkyl. 25. The compound of claim 24 , wherein the compound has the structure: 26. The compound of claim 1 , wherein the compound is selected from:

Assignees

Inventors

Classifications

  • Immunosuppressants, e.g. drugs for graft rejection · CPC title

  • Immunomodulators · CPC title

  • Drugs for immunological or allergic disorders · CPC title

  • Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • Antipsoriatics · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9475781B2 cover?
Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and inter…
Who is the assignee on this patent?
Rigel Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification A61K31/4439. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).